Financials

Financials — What the Numbers Say

Molina is a near-pure-play government managed-care insurer: ~80% of premium from state Medicaid, the rest split between ACA Marketplace and Medicare Advantage / D-SNP. The economics are a spread — the gap between PMPM premium and medical cost (the MLR). Twenty years of ~13% revenue CAGR has been driven by membership growth and state contract wins; the operating margin has rarely cleared 5%, and the equity story turns on whether MLR stays close to ~88%.

FY2025 is what happens when MLR breaks. A nationwide medical-cost surge — post-redetermination Medicaid acuity, Marketplace utilization, MA trend — pushed consolidated MLR several points higher, collapsing operating margin from 4.2% to 1.7%, EPS from $20.42 to $8.92, and free cash flow from +$544M to −$636M in a single year. Management nonetheless bought back $1.04B of stock, funded by $1.94B of new debt. The investment debate now sits on whether 2025 was a cyclical reset of medical-cost trend that bends back, or a structural step-down in Medicaid rate adequacy.

The 30-Second View

Definitions for the beginner. Medical Loss Ratio (MLR) is the share of every premium dollar Molina pays out in medical claims; an MLR of 88% means $0.88 of every $1.00 of premium goes to care. Operating margin for an insurer is essentially 1 − MLR − admin%; a 100bps move in MLR is roughly 100bps off operating margin. Cash conversion is operating cash flow divided by net income — for a managed-care insurer it usually runs well above 1.0x because medical-claims-payable (a current liability) grows with revenue and acts as float.

Twenty Years of Statements — The Standard Table

The numbers below are what every analyst opens first. Notice three things: (1) two full decades of nearly uninterrupted revenue growth driven by Medicaid expansion and acquisitions; (2) margins that whip on a narrow band — every 100bps move in MLR shows up; (3) the FY2025 line, where revenue growth continued but earnings and cash flow inverted.

Note on FY2017. The deep loss was a discrete restructuring/impairment episode, not an MLR event; new management cleaned house in 2018 and earnings bounced more than 2x. The point is that this is a business where single-year earnings can be misleading in either direction — multi-year context matters.

Growth Has Been Real — But It Came From Members and Acquisitions, Not Pricing Power

Revenue has compounded at roughly 13% per year over twenty years and ~19% over the last five. But this is not a pricing-power business — the state sets the per-member rate via competitive RFPs. Growth comes from three places: (1) winning new state Medicaid contracts (notably the Illinois win cited in early 2026 commentary), (2) ACA Marketplace enrollment cycles, and (3) bolt-on acquisitions (Cigna's Texas Medicaid book, Bright Health California Medicaid, AgeWell New York, the My Choice Wisconsin and Magellan-related deals). The implication is that revenue growth is decoupled from profitability: Molina can grow membership and revenue while margins compress, which is exactly what FY2025 showed.

The Crux — Margins and the MLR Spike

This is the page's most important chart. Operating margin has historically ranged 3.7% – 6.2% in good years. FY2025 broke that band on the downside.

Reading this chart. Gross margin for a managed-care insurer is essentially 1 − MLR. The drop from 15.3% to 13.1% in FY2025 implies MLR widened by roughly 220bps — from the high-84% area into the upper-86% range — driven by a documented industry-wide medical cost trend that hit every major US health insurer this cycle. Operating margin is even more sensitive because the SG&A ratio rose at the same time as fixed-cost dilution worked in reverse.

The Quarter-by-Quarter Walk Tells the Same Story Faster

Operating income ran in a tight $360M–$470M band for nine consecutive quarters, then halved to $137M in Q3 FY2025 and turned negative ($162M loss) in Q4. Q1 FY2026 stabilized at $83M and management has guided full-year FY2026 to roughly $5.00 of adjusted EPS — a level not seen since 2014. The direction of the Q1 print is encouraging; the level is a long way from the prior earnings power.

Earnings Quality — When Cash Stops Following Reported Income

For a managed-care insurer, operating cash flow normally runs above net income because the claims-payable liability acts as float. The OCF/NI ratio averaged ~1.8x over 2020–2023. In FY2024 it dropped to 0.55x. In FY2025 it inverted to −1.13x — i.e., the company reported $472M of GAAP net income while burning $535M of operating cash.

The gap is largely about working capital: medical claims-payable accruals shrank while receivables (state premium accruals, marketplace risk-corridor receivables, retroactive Medicaid items) ballooned. The Q1 FY2026 results disclosure flagged prior-year retroactive Medicaid items and trend-related reserve catch-ups, so part of FY2025's cash hit is timing-driven and should reverse if MLR stabilizes. The risk is the other part — if states continue to lag on rate adequacy, the working-capital drag persists.

Balance Sheet — Still a Net Cash Position, but the Buffer is Narrowing

The headline number is still favorable: at year-end FY2025, Molina sat on $8.3B of cash and equivalents against $3.95B of long-term debt, a net cash position of roughly $4.3B. But that net-cash buffer has shrunk from $6.7B at year-end FY2023 in two years, despite no major equity raise. The reason: a $1.0B buyback in FY2025 funded by $1.94B of new senior notes (the $850M 6.5% notes due 2031 plus refinancing) layered on top of an OCF deficit. Tangible book value per share fell from $44 to $35.

Important context on the cash. Not all $8.3B is free for general corporate use. A large portion sits in regulated subsidiary statutory reserves required by state insurance regulators. The amount available to the parent for buybacks, M&A, and debt service is materially smaller (typically 25%–40% of consolidated cash in this industry). That matters because the parent-level liquidity, not consolidated cash, is what services the senior notes.

Management also amended its credit agreement in 2026 to temporarily reduce the minimum interest coverage covenant, with the relief stepping back to standard levels by Q3 2027 — a signal that lenders agree the earnings dip is real but expected to be transient.

Net debt to EBITDA is still negative (cash exceeds debt). Even on a stressed FY2025 EBITDA of ~$976M, gross debt is only ~4.0x EBITDA — manageable in absolute terms but no longer fortress-like. If FY2026 EBITDA holds near current guidance and FCF remains weak, leverage could approach territory where the credit-rating implications start to bite.

Capital Allocation — The Buyback That Wasn't Quite Free

The capital-allocation philosophy has been: no dividend, no share issuance, modest tuck-in M&A, and aggressive buybacks when valuation seems attractive. The track record is mixed — the $614M FY2020 buyback at an average price around the low $200s and the $1.1B in FY2024–FY2025 buybacks at an average price likely well above the current $200 share have generated mediocre per-share value capture. Share count is down from 66.6M (FY2018) to 52.9M (FY2025), a ~21% reduction — meaningful, but at a higher average price than where the stock trades today.

The FY2025 decision to keep buying back $1B of stock while reported FCF was negative — funded by new debt issuance — is the single most contentious capital-allocation call. The bull case: management views the share price as a clear bargain relative to normalized earnings. The bear case: levering up to buy a falling stock against a backdrop of margin uncertainty is risky regardless of the eventual outcome.

Returns on Capital — Structurally Below the Industry's Headlines, but Above Peers Today

ROE averaged ~31% from FY2018 through FY2024 — well above the cost of equity. That sounds spectacular, but it reflects financial structure, not pricing power: a small equity base (most of MOH's assets sit in regulated insurance subsidiary balance sheets) sits underneath a much larger revenue stream, so a 3-4% net margin translates into a 25-30% ROE. The FY2025 collapse to 11% — half of the prior decade's median — is the right way to see what happens when the margin assumption breaks. Return on invested capital fell less violently but is still down ~12 points year-on-year.

Valuation — Cheap on Trailing Numbers, Expensive on Trough Earnings

A few readings here, in order from most useful to least:

1. EV/Sales (Price/Sales). At 0.19x of FY2025 revenue, the lowest in two decades and roughly a third of the recent peak. For a spread business, this is the cleanest "balance sheet through the cycle" multiple — it does not depend on which year's earnings you anchor on. The question is whether revenue is durable.

2. P/B at 2.2x. Down from 4–7x in the prior decade. Book value still grew last year (despite the buyback) — but a managed-care insurer should trade at a premium to book mainly because of high through-cycle ROE; if the market is right that 11% ROE is the new normal, 2.2x is roughly fair, not cheap.

3. EV/EBITDA at 4.7x. Cheap on a trough number. On normalized EBITDA — i.e., re-applying a 4.5–5% operating margin to FY2025 revenue — EV/EBITDA collapses below 3x, which would be unusually cheap. That math is the whole bull case.

4. P/E at 19.5x trailing, ~40x forward 2026. Useless on trailing, ugly on forward — but the forward number sits on a guided trough. Management's 2029 adjusted EPS target near $25 implies the stock is trading at roughly 8x normalized 2029 EPS. That number would be cheap, but it requires three things to all happen: state Medicaid rate normalization, marketplace utilization recovery, and execution against the cost-control plan.

Versus Peers — The Whole Industry Got Caught, But MOH is Smallest and Most Concentrated

Three observations:

• Every meaningful peer saw operating margins compress in FY2025. Centene (the closest comparable on Medicaid mix) went to a −3.9% operating margin and a $6.4B GAAP loss. So MOH's drop, while severe, was better than the closest peer.
• MOH trades at the lowest EV/Sales in the group (0.11x) — meaningfully below the next-cheapest (CNC at 0.13x). This is partly fair (highest concentration, smallest float, lowest scale of capital allocation diversification) and partly the discount that has to compress when MLR normalizes.
• The diversified peers (UNH, ELV, CVS) screen as more expensive on EV/Sales but earn a premium for revenue mix and (for UNH/CVS) for the Optum/Caremark services arms. MOH has no such hedge — it lives and dies on government managed-care MLR.

The scatter shows a roughly linear relationship: the higher the operating margin, the higher the EV/Sales the market pays. MOH and CNC both sit at the low-margin, low-multiple corner. The investment trade is essentially a directional bet on whether MOH walks back along that line toward ELV/HUM territory as MLR normalizes — or stays at the CNC corner of the chart.

Summary and the One Metric To Watch

What the financials confirm. This is a low-margin, capital-light spread business whose decade-long compounding came almost entirely from membership growth and state Medicaid wins. Through-cycle ROE near 30% is genuine — but it's a function of leverage on a thin margin, not pricing power. The balance sheet entered FY2025 in a fortress position and remains in net cash, but cash flow turned negative and management chose to defend the buyback by raising debt.

What the financials contradict. Any narrative that prices MOH as "structurally broken" runs into the FY2026 Q1 print (operating income back to $83M, adjusted EPS of $2.35) and the fact that every major managed-care peer saw the same FY2025 hit. This was a sector event, not an idiosyncratic accounting blow-up.

Where the swing factor sits. The valuation reads as cheap on EV/Sales and EV/Sales-to-normalized-margin, fair on book, ugly on forward P/E. None of those answers is portable to the next year unless you have a view on MLR. Everything else — growth, share count, leverage, returns — is downstream of that one ratio.

The first financial metric to watch is the consolidated Medical Loss Ratio (MLR), reported quarterly. A sustained move back toward 88% — the historical range MOH operates in — would restore the operating-margin band to ~4-5% and the trough-EPS narrative resolves into the management's 2029 target of ~$25 adjusted EPS, at which point the current ~$200 share price looks distinctly cheap. A second consecutive year above 89% would make the FY2025 step-down look structural and would force the multiple-on-trough-earnings math to dominate. Everything else on this page is a derivative of that single ratio.